vTv Therapeutics to Participate in Upcoming Investor Conferences

Core Viewpoint - vTv Therapeutics Inc. is advancing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, and is actively participating in investor conferences to discuss its developments [1][2]. Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [2]. - The clinical pipeline is led by cadisegliatin, which is currently in a US Phase 3 trial for type 1 diabetes [2]. Product Details - Cadisegliatin (TTP399) is a novel, liver-selective glucokinase activator being investigated as an oral adjunctive treatment for type 1 diabetes [3]. - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, suggesting potential for improved glycemic control [3]. - The product has received Breakthrough Therapy designation from the U.S. FDA, indicating its potential significance in treatment [3].